Enzolytics Announces The Signing Of The Business Combination Agreement With Sagaliam Acquisition Corp
Enzolytics Announces The Signing Of The Business Combination Agreement With Sagaliam Acquisition Corp
Enzolytics, Inc. (OTC:ENZC) (
Enzolytics, Inc.（场外交易代码：ENZC）(
Enzolytics, Inc. announces today that it has executed the binding business combination agreement for the sale of Biogenysis, Inc. ("BGEN") and Virogentics Inc. ("VIRO"), the operating subsidiaries of Enzolytics Inc., to Sagaliam Acquisition Corp (NASDAQ:SAGA) in a transaction valued at $450,000,000. The combined company is expected to trade on NASDAQ. The entities have begun the de-SPAC process and are moving on with the closing of this project.
Enzolytics, Inc.今天宣布，它已执行具有约束力的业务合并协议，将Enzolytics Inc. 的运营子公司Biogenysis, Inc.（“BGEN”）和Virogentics Inc.（“VIRO”）出售给Sagaliam收购公司（纳斯达克股票代码：SAGA），交易价值4.5亿美元。合并后的公司预计将在纳斯达克上市。这些实体已经开始了de-SPAC进程，并正在推进该项目的结束。
Harry Zhabilov, CSO of VIRO, stated, "The SAGA transaction opens numerous opportunities to advance our existing technology, developing new technology and expansion of our growing nutraceutical product line at what we believe will be a significantly faster pace."
VIRO首席科学官Harry Zhabilov表示：“SAGA的交易为推进我们现有技术、开发新技术和扩大我们不断增长的营养保健品产品线开辟了许多机会，我们认为这将大大加快步伐。”
Dr. Gaurav Chandra, CEO of BGEN, stated: "Biogenysis strives to make a significant impact in drug discovery and development by utilizing advanced AI technology. Our focus is on safeguarding our assets with multi-layered security while expanding our IP portfolio to include AI-driven monoclonal antibodies. With these antibodies, we aim to revolutionize the fight against HIV, COVID-19 mutations, and other viruses. Collaborating with pharmaceutical companies, our focus is to cover all viruses in our repository, providing patients with necessary diagnostics and therapies. Our AI Platform is constantly evolving with disruptive innovations in healthcare. We are proud to be at the forefront of this crucial work and look forward to continuing to positively impact the world."
BGEN首席执行官高拉夫·钱德拉博士表示：“Biogenysis努力利用先进的人工智能技术对药物发现和开发产生重大影响。我们的重点是通过多层安全保护我们的资产，同时扩大我们的知识产权组合，将人工智能驱动的单克隆抗体包括在内。通过这些抗体，我们的目标是彻底改变对抗 HIV、COVID-19 突变和其他病毒的斗争。与制药公司合作，我们的重点是覆盖我们存储库中的所有病毒，为患者提供必要的诊断和治疗。随着医疗保健领域的颠覆性创新，我们的人工智能平台不断发展。我们很自豪能够站在这一关键工作的最前沿，并期待继续对世界产生积极影响。”
Charles Cotropia, Enzolytics' CEO, said, "We have a well-defined strategy and the necessary technology in place for producing numerous therapeutics for successfully treating numerous viruses that affect patients around the world. Completing the business combination with Sagaliam comes at a critical time. By providing additional funding to Biogenysis and Virogentics, this combination will make possible the final development of the numerous therapeutics now being produced."
Enzolytics首席执行官Charles Cotropia表示：“我们有明确的战略和必要的技术，可以生产多种疗法，成功治疗影响世界各地患者的多种病毒。完成与Sagaliam的业务合并正值关键时刻。通过向Biogenysis和Virogentics提供额外资金，这种组合将使目前正在生产的众多疗法的最终开发成为可能。”
Barry Kostiner, the CEO of Sagaliam, stated, "Being listed on Nasdaq provides increased visibility and access to a broader pool of investors, facilitating the advance of our pioneering research and drug development initiatives. Bringing Virogentics and Biogenysis to our Nasdaq platform opens the door to funding which serves as the lifeblood of all pharmaceutical development companies. We are working with the investor community, as well as the dedicated VIRO and BGEN management teams, to secure the financial resources required to expedite clinical trials. With these investments, we aim to accelerate our progress, ensuring that both therapeutic and nutraceutical innovations swiftly find their way into the market, ultimately improving the lives of countless individuals."
Sagaliam首席执行官巴里·科斯蒂纳表示：“在纳斯达克上市可以提高知名度，接触更广泛的投资者，从而促进我们开创性的研究和药物开发计划的推进。将Virogentics和Biogenysis引入我们的纳斯达克平台为融资打开了大门，而融资是所有制药开发公司的命脉。我们正在与投资者群体以及专门的VIRO和BGEN管理团队合作，以确保加快临床试验所需的财务资源。通过这些投资，我们的目标是加快进展，确保治疗和营养保健品的创新都能迅速进入市场，最终改善无数人的生活。”
译文内容由第三方软件翻译。